enGene appoints Lota Zoth to Board as Audit Committee Chair

enGene Therapeutics Inc.

Lota S. Zoth, CPA, appointed as Class I Director, effective Dec 18, 2023.
Zoth will serve as Audit Committee Chair; Board expanded from four to five members.
She brings 20+ years of financial and audit experience, including CFO at MedImmune.
Currently serves on boards of Lumos Pharma, Inovio Pharmaceuticals, and 89 Bio.
Standard independent director compensation plan applies; no related-party transactions.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Lota Zoth

Class I Director and Audit Committee Chair

ENGN · enGene Therapeutics Inc.

Effective: 2023-12-18
Filed: December 21, 2023, 6:59 PM ET

On December 18, 2023, the Board of Directors (the “Board”) of enGene Holdings Inc. (the “Company”), increased its size from four members to five and, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Lota Zoth to the Board as a Class I Director of the Board, with a term expiring at the Company’s first annual general meeting following her appointment, or until her successor is duly elected and appointed.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lota Zoth was appointed as Class I Director and Audit Committee Chair at enGene Therapeutics Inc..

Action: appointed
Role: Class I Director and Audit Committee Chair

Exact text from the filing

On December 18, 2023, the Board of Directors (the “Board”) of enGene Holdings Inc. (the “Company”), increased its size from four members to five and, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Lota Zoth to the Board as a Class I Director of the Board, with a term expiring at the Company’s first annual general meeting following her appointment, or until her successor is duly elected and appointed.

View on SEC.gov

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000929638-23-003464

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.